Author

C. Kasap

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Organism:human· 4 Approach:experimental assay· 3 Assay:proteomics· 3 Research Focus:cell type annotation· 2 Approach:deep learning· 2 Assay:scRNA-seq· 2 Approach:statistical model· 2

Frequent Co-Authors

P. Phojanakong· 3 shared V. Steri· 3 shared A. Kang· 2 shared A. P. Wiita· 2 shared A. Wiita· 2 shared E. Ramos· 2 shared E. Stieglitz· 2 shared F. Salangsang· 2 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

P. Phojanakong

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Histologic variants in bladder cancer harbor aggressive molecular features including TM4SF1 expression and a CA125+ cell state

H. Yang, H. Song, E. Yip, K. Chang, P. Allegakoen, K. L. Lu, K. Hui, J. Pham, C. Kasap, V. Kumar, J. Gayle, B. A. Stohr, C.-K. C. Ding, A. P. Wiita, M. V. Meng, , F. W. Huang

Single cell RNA sequencing of bladder cancer subtypes identified a CA125+ cell state linked to aggressive features and TM4SF1 as a therapeutic target.

bioRxiv · May 20, 2024 · PreprintCancer Biology

Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells

C. Kasap, A. Izgutdina, B. Patino-Escobar, A. Kang, N. Chilakapati, N. Akagi, H. Johnson, T. Rashid, J. Werner, A. Barpanda, H. Geng, Y.-H. T. Lin, S. Rampersaud, D. Gil-Alos, A. Sobh, , A. Wiita

Structure-optimized CD27-based CAR-T cells targeting CD70 show >80-fold improved expansion in vivo and offer a potential therapy for high-risk multiple myeloma patients.

bioRxiv · Feb 24, 2024Cancer Biology

Structural surfaceomics reveals an AML-specific conformation of Integrin-β2 as a CAR-T therapy target

K. Mandal, G. Wicaksono, C. Yu, J. J. Adams, M. R. Hoopmann, W. C. Temple, B. P. Escobar, M. Gorelik, C. H. Ihling, M. A. Nix, A. Naik, E. Ramos, C. Kasap, V. Steri, J. A. C. Serrano, , A. P. Wiita

The paper identifies an AML-specific conformation of Integrin-β2 using structural surfaceomics and demonstrates its targeting by CAR-T cells.

bioRxiv · Oct 10, 2022 · PreprintCancer Biology

Functional multi-omics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma

P. Choudhry, C. Kasap, B. Patino Escobar, O. Gugliemini, H. Geng, V. Sarin, A. Kang, A. Kishishita, S. Rampersaud, L. Sarah, Y.-H. T. Lin, N. Paranjape, P. Ramkumar, M. Marcoulis, D. Wang, , A. Wiita

This study uses multi-omics approaches to identify regulators of CD38 surface expression in multiple myeloma and assess the impact of therapies on CD38 levels and signaling.

bioRxiv · Aug 4, 2021 · PreprintCancer Biology